Abstract. Pim-3 kinase has been shown to be aberrantly expressed in premalignant and malignant lesions of endoderm-derived organs such as the liver, pancreas, colon and stomach. Pim-3 kinase inactivates the Bad protein, a proapoptotic molecule, and improves the expression of Bcl-xL, an antiapoptotic molecule, to promote cell proliferation. Thus, blocking Pim-3 kinase activity may be a new strategy for the treatment of pancreatic cancer. In this study, we screened low molecular compounds and observed that the stemonamide synthetic intermediate, T-18, potently inhibited Pim kinase activity. Moreover, T-18 inhibited the proliferation of human pancreatic, as well as that of hepatocellular and colon cancer cells in vitro. It also induced the apoptosis of human pancreatic carcinoma cells in vitro by decreasing the levels of phospho-Ser 112 -Bad; the levels of Pim-3 kinase and total Bad protein were not altered. Furthermore, T-18 inhibited the growth of human pancreatic cancer cells in nude mice without apparent adverse effects when the tumor was palpable. These observations indicate that stemonamide synthetic intermediates may be novel drugs for the treatment of gastrointestinal cancers, particularly pancreatic cancer.
Introduction
Pancreatic cancer is one of the common malignant tumors in Western countries with the highest incidence rate, and is also one of the cancers with the highest mortality rate (1) . The characteristics of pancreatic cancer include high-grade malignancy, specific biological behavior, non-specific symptoms and tendency for early metastasis, insensitivity to chemotherapy and radiotherapy and a low rate of surgical resection (2) . Compared with other cancers, the survival rate is so low that the incidence rate is basically equal to the mortality rate (3) . Thus, molecular targeted therapy may be the most effective treatment for pancreatic cancer.
The proto-oncogene Pim family exhibits serine/threonine kinase activity. In humans, the Pim family includes 3 members: Pim-1, Pim-2 and Pim-3 (4) . Crystal structures of Pim family kinases have revealed that the ATP-binding sites of Pim family kinases share high structural homology (5) (6) (7) . The overexpression of Pim-1 and Pim-2 has been found in a variety of human hematopoietic malignancies (8) (9) (10) (11) , such as leukemia and lymphoma and some solid tumors, such as prostate cancer (12) (13) (14) . Pim-3 has mainly been found in solid tumors, particularly endoderm-derived organs such as the liver, stomach, pancreas and colon (15) (16) (17) and Pim kinases have been demonstrated to inhibit apoptosis by phosphorylating the pro-apoptotic molecule, Bad at Ser 112 . Thus, Pim-3 may be an effective target for the treatment of cancer of endodermderived organs, particularly the pancreas (18) (19) (20) (21) . Several Pim kinase inhibitors have been reported (22, 23) , but only a few of them are effective against all Pim family kinases (24) (25) (26) (27) . This prompted us to develop a specific inhibitor for each Pim kinase.
In this study, we investigated whether T-18, a stemonamide synthetic intermediate, may be used as a Pim-3 kinase inhibitor. T-18 reduced the levels of phosphorylated Bad at Ser 112 , resulting in the decreased growth of pancreatic carcinoma cells in vitro and the induction of apoptosis. Furthermore, T-18 also inhibited the growth of human pancreatic cancer cells in nude mice even when the forming tumor was observed. These results indicate that T-18 may be a lead compound that can be modified to exert a more potent inhibitory effect on Pim-3 kinase, and may thus be effectively used in the treatment of cancers with an aberrant Pim-3 overexpression.
Materials and methods
Cell culture and antibodies. The human pancreatic cancer cell lines, PCI35 (28), PCI55 (28), PCI66 (28), PANC-1 (29) and MIA PaCa-2 (30) , and the human colon cancer cell line, SW480 (31) , were cultured in RPMI-1640 medium, while another human pancreatic cancer cell line, L3.6pl (32) , and the human colon cancer cell line, SW48 (31), were maintained in minimum essential medium. The human colon cancer cell lines, HCT29 (33) and HCT116 (34), were cultured in McCoy's 5A medium and the human hepatocarcinoma cell lines, HepG2, Hep3B (35) and HuH7 (36), were maintained in Dulbecco's modified Eagle's medium. All media were supplemented with 10% FBS, 50 U/ml of penicillin and 50 U⁄ml of streptomycin. The following antibodies were used: mouse anti-human Bad (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit antiphosphorylated (p-) Ser 112 -Bad (Cell Signaling Technology, Beverly, MA, USA) and anti-β-actin antibodies (Sigma-Aldrich). The rabbit anti-human Pim-3 antibodies were prepared as previously described (16) .
Preparation of stemonamide synthetic intermediates. The stemonamide synthetic intermediates were synthesized as previously described (37) . T-10 and T-18 were dissolved in DMSO (Sigma-Aldrich) at the concentration of 100 mM as stocking solution and the solutions were stable within 1 week. T-18 was dissolved in DMSO at the concentration of 100 mg/ml and the solution was diluted with olive oil to reduce the final DMSO concentration to 4% v/v for the animal experiment.
In vitro Pim kinase assay and Akt kinase assay. Based on the ability of Pim kinases to phosphorylate Bad at Ser 112 , in vitro kinase assay for Pim-1, Pim-2 and Pim-3 was established and conducted as previously described (38, 39) . The IC 50 values were calculated using logistic regression.
Akt kinase activities were determined based on their capacity to phosphorylate Bad at Ser 136 as described previously (38, 39) . Either recombinant Akt-1 (10 ng) (Cell Signaling Technology) or Akt-2 (10 ng) (Assay Designs, Ann Arbor, MI, USA) was used as the source of the enzymes. Akt-1/2 kinase inhibitor (Sigma-Aldrich) was used as the positive control inhibitor.
Cell viability assay. Cells were inoculated into 96-multiwell plate at 3,000 cells/100 µl per well and incubated at 37˚C for 18 h. The chemicals were then added to each well at the indicated concentrations and the cells were incubated for the indicated periods of time. After removing the supernatants, the medium containing CCK-8 (Dojin Chemicals, Kumamoto, Japan) was added to each well followed by a 2-h incubation. Subsequently, the optical density was measured at 450 nm. The number of viable cells at day 0 was regarded as the control to determine the ratios of viable cell numbers. Logistic regression was used to calculate the IC 50 values.
Cell apoptosis assay. The cell apoptosis assay was operated according to the instruction manual of human Annexin V-FITC apoptosis kit (Bender MedSystems GmbH, Vienna, Austria). The cells were harvested after exposure to the chemicals and 20,000 stained cells were acquired for the analysis on the FACSCalibur system (BD Biosciences).
Western blot analysis. The L3.6pl or MIA PaCa-2 cells (2x10 6 cells) were seeded in 100-mm culture plates. After an 18-h incubation, the chemicals were added to the plate at the final concentration of 10 µM. Subsequently, 60 µl CellLytic™ Cell Lysis Reagent (Sigma-Aldrich) with Complete Proteinase Inhibitor Cocktail (Roche Diagnostics AG, Rotkreutz, Switzerland) was added followed by ultrasound sonication after treatment with the chemicals. Following centrifugation, the supernatants were collected for western blot analysis using the antibodies mentioned above.
Animal experiments. L3.6pl cells were suspended in HBSS at the concentration of 5x10 6 cells/ml and 100 µl cell suspensions were inoculated subcutaneously into the back of BALB/c nu/nu mice (SLC, Shizuoka, Japan). Twelve days after tumor injection, the chemical (20 mg/kg) or olive oil vehicle was injected intraperitoneally once a day for 5 days as one course. The course was repeated 3 times with an interval of 2 days. Tumor sizes were measured every 3-4 days with a caliper and tumor volumes were determined using the following the formula: tumor volume (mm 3 ) = (the longest diameter) (mm) x (the shortest diameter) 2 (mm)/2. On day 32 after the tumor cell injection, blood was taken simultaneously at tumor removal. Serum levels of alanine aminotransferase (ALT) were measured using the Fuji Drichem 5500V analyzer (Fujifilm Medical Systems, Tokyo, Japan).
Statistical analysis. Data are expressed as the means ± SD unless otherwise indicated. One-way ANOVA and the TukeyKramer test were employed to analyze the differences between groups and a value of P<0.05 was considered to indicate a statistically significant difference.
Results

Effects of T-18 on Pim kinase activity.
We previously reported that some synthetic intermediates of stemonamide (T-2) can inhibit the activity of Pim-3 kinase in vitro (38) . However, the IC 50 of T-2 was at a micromolar concentration, which prompted us to find additional chemicals which can exert a more profound inhibitory effect at low doses. T-18 was synthesized based on T-2. We found that T-18, one of the stemonamide synthetic intermediates (Fig. 1A) , inhibited Pim kinase activity (Fig. 1B) . Compared with T-10 (38), T-18 inhibited Pim kinase activity to a lower extent. Moreover, T-18 inhibited Pim-1 and Pim-2 kinase activity to a similar extent as Pim-3 (Table I) . We then examined the effects of T-18 on the human Akt/protein kinase B (PKB) protein kinase, another serine/threonine kinase which can phosphorylate a similar set of proteins, such as Bad (40, 41) . Akt-1/2, a specific inhibitor of Akt-1 and Akt-2, was used in our study as the positive control for a comparison against T-18 (Table I) . Akt-1/2 efficiently inhibited Akt-1 and Akt-2 activity, while T-18 did not exert any effect on the Akt protein kinase.
Thus, T-18 can potently and selectively inhibit Pim-3 kinase activity, but not that of Akt.
Effects of T-18 on cell proliferation in vitro.
Two human pancreatic cancer cell lines, MIA PaCa-2 and L3.6pl, were recruited to examine the effects of T-18 on cell proliferation in vitro (Fig. 2) . The results showed that T-18 effectively inhibited cell proliferation in a dose-dependent manner. However, T-10 had little effect on the cell proliferation of these cancer cell lines, and had little influence on Pim-3 kinase activity. T-18 was added to the medium of the other human pancreatic cancer cell lines (PCI66, PCI35, PCI55 and PANC-1), hepatocellular carcinoma cell lines (HuH7, HepG2 and Hep3B) and colon cancer cell lines (SW480, SW48, HT29 and HCT116) to determine the effect of T-18 on the proliferation of these cells (Table II) . Almost all the cancer cell lines were sensitive to T-18. These observations suggest that T-18 inhibits Pim-3 kinase activity and has an effect on the proliferation of these cells.
Effects of T-18 on cell apoptosis.
In our previous studies, we demonstrated that a Pim-3 shRNA-mediated reduction in Pim-3 protein expression decreased the levels of phospho-Ser 112 -Bad and increased the number of apoptotic cells in human pancreatic and colon cancer cell lines (16, 17) . In this study, we investigated whether T-18 can affect the phosphorylation state of Bad in the human pancreatic cancer cell lines, MIA PaCa-2 and L3.6pl. Consistent with our previous results, the levels of phospho-Ser 112 -Bad decreased in the cell lines following treatment with T-18. However, the levels of Pim-3 kinase protein or total Bad protein were not altered with the treatment time (Fig. 3) . Moreover, early apoptotic and late apoptotic cells were enhanced in both cell lines (Fig. 4) following treatment with T-18 for 24 and 48 h. These observations indicate that T-18 prevents the phosphorylation of Bad, eventually leading to apoptosis in human pancreatic cancer cells.
Effects of T-18 on tumor growth in vivo.
Finally, we investigated the effects of T-18 on tumor growth in vivo. We subcutaneously injected L3.6pl pancreatic cancer cells into nude mice as Table I . Inhibitory activity of T-18 on Pim and Akt kinases.
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Pim- described above and T-18 treatment commenced on day 12 after the tumor injection, when the tumor was palpable (Fig. 5A) . The tumors of the mice in the vehicle-treated group grew more rapidly than those of the mice in the T-18-treated group (Fig. 5B) . During the course of the experiment, all mice tolerated T-18 well, as evidenced by the fact that no body weight loss was observed (Fig. 5C ) and the changes in serum ALT levels (Fig. 5D) . These results suggest that T-18 suppresses tumor growth in vivo without any significant side-effects.
Discussion
Pancreatic cancer is a malignant tumor of the pancreas, and poses a threat to human health. The majority of patients are diagnosed at an advanced stage, thus surgical treatment is not valid and the only treatment options are radiotherapy or chemotherapy, with the survival time being less than a year (42, 43) . Thus, molecular targeted therapy is considered to be a very promising treatment. These targeted molecules are not expressed in normal tissues but are aberrantly expressed in tumor tissues and play a key role in regulating tumor cell proliferation. The Pim-3 kinase is aberrantly expressed in premalignant and malignant lesions of endoderm-derived organs, such as the liver, pancreas, colon and stomach (16, 17, 44, 45) but not in normal tissues. The Pim-3 kinase inactivates the Bad protein by phosphorylating Bad at Ser 112 to promote cell proliferation (25) , providing the characteristics of a targeted molecule. Thus, blocking Pim-3 kinase activity may be a new strategy for the treatment of pancreatic cancer.
The crystal structure of Pim-1 and Pim-2 reveals that there is a special hinge region that can connect the 2 lobes of the protein kinase domain, which presents a unique way for ATP to bind with Pim kinases instead of other protein kinases (5, 46, 47) . Thus, it may be possible to develop an inhibitor that selectively targets Pim kinases, not other seine/threonine kinases (48) . Existing small molecule inhibitors against Pim kinases that have been reported include flavonol quercetargetin (7), imidazole [1,2-b] pyridazines (26, 49) , bezylindene-thiazolidine-2,4-dione (50-52), 3,5-disubstituted indole derivatives (53), pyrazolo[3,4-g]quinoxaline derivatives (54) and N-10 substituted pyrrolo[2,3-a]carbazole derivatives (55) (56) (57) . These molecules have been certified to inhibit the proliferation of human cancer cells in vitro and/or in vivo. However, most of the compounds are multi-Pim kinase inhibitors and Pim-3 has received the least attention among the Pim family kinases. Thus, a novel and safe Pim-3 targeting inhibitor is required. We have previously demonstrated that other stemonamide synthetic intermediates (T-2, T-5) can inhibit Pim kinases activity and suppress cancer cell proliferation in vitro, as well as tumor growth in vivo (38) . However, the IC 50 of T-2 was at a micromolar concentration. In this study, we investigated another low molecular compound (T-18) that shares homoplastic structure with T-2 and may exert a more effective anticancer effect.
To recognize a Pim-3 inhibitor, a series of low molecule chemicals were screened and a stemonamide synthetic intermediate, T-18, was observed, which was similar to T-2 which was investigated in our previous study (38) . In the current study, T-18 inhibited the activity of Pim-3, Pim-1 and Pim-2 As we have previously demonstrated, T-2 (38), similar to T-18, can inhibit Pim-3 activity and reduce the growth of pancreatic cancer cells in vitro and in vivo. T-2 also inhibited in vivo tumor growth effectively. However, as shown in this study, T-18 inhibited the proliferation of human cancer cells in vitro with a lower IC 50 value. Perhaps T-18 is an ideal compound that can be modified to exert a more potent inhibitory effect without any severe side-effects.
Another serine/threonine kinase, namely Akt, can phosphorylate similar sets of substrates, such as Bad, as Pim kinases, thus initiating the proliferation of cancer cells (41) . Akt is aberrantly activated in various types of tumors and Akt inhibitors have been extensively investigated (40) . Although the Akt inhibitor, GSK690693, has exhibited potent antitumor activity in pre-clinical animal experiments (41), the genetic disruption of each Akt kinase gene results in severe phenotypic changes, such as neonatal mortality, severe growth retardation and reduced brain size (58) (59) (60) and Akt-2 inhibition induces severe hyperglycemia (41) . This is a serious impediment for the clinical use of Akt inhibitors in anticancer treatment. The Pim-3 kinase is aberrantly expressed in malignant lesions but not in endoderm-derived normal tissues, such as the liver, pancreas, colon and stomach (16, 17, 44, 45) and promotes tumor development. Moreover, Pim-3 gene deficiency does not induce apparent phenotypic changes, suggesting that Pim-3 may be physiologically dispensable (61) . Pim kinases are not localized downstream of the insulin receptor signaling pathway but the Akt kinase is. The inhibition of Pim kinases has few effects on normal metabolism. Thus, Pim kinases may be more effective targets compared to Akt in the molecular targeted therapy of various types of cancer, particularly pancreatic cancer, exerting potent effects and few adverse effects. In this study, we showed that T-18 inhibited Pim kinases activity but failed to suppress Akt-1 and Akt-2 activity, suggesting that T-18 may be a safe drug for use in molecular targeted therapy. However, it may be difficult to discovery a specific inhibitor against either Pim-1 or Pim-3 kinase due to their extraordinarily similar peptide substrate identity (46) . It would be of interest to determine whether a specific inhibitor against anyone of the Pim family kinases will prove to be advantageous over existing Pim kinase inhibitors.
